The ongoing clinical study is a first-in-human trial evaluating Neogap’s personalised cell therapy in patients with advanced colorectal cancer. The primary focus is on safety and tolerability, while the study also generates early clinical and exploratory data. Several patients have been treated, and previously communicated safety data indicate that the treatment is well tolerated, states the company.

In parallel, Neogap has received approval from the Swedish Medical Products Agency to treat all patients in the study at full dose. As part of its EIC grant, Neogap has, in collaboration with NorthX Biologics, developed a manufacturing framework to support later-stage clinical trials and future commercialization, the company describes.

Over the past year, we have reached several important milestones, including treating patients, generating initial safety data and receiving regulatory approvals.

“Over the past year, we have reached several important milestones, including treating patients, generating initial safety data and receiving regulatory approvals. We are also seeing encouraging signals in our exploratory data. We now look forward to intensifying preparations for the next stage of clinical development,” says Samuel Svensson, CEO of Neogap Therapeutics.